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Outcome in community-acquired pneumonia (CAP) is 
adversely aﬀ  ected by increasing severity of illness, co-
morbidity and age. Organisational factors such as timely 
administration of appropriate antibiotics, prompt 
admission to critical care and adherence to antibiotic 
policies, however, are also important in inﬂ  uencing out-
come [1-3]. Combination therapy with two antimicrobial 
agents seems superior to monotherapy in severe CAP, 
and this approach is recommended by a number of 
organisations [4,5]. Th  e Infectious Diseases Society of 
America/American Th  oracic Society guidelines suggest 
therapy with a β-lactam antibiotic, with the addition of 
either a macrolide or ﬂ   uoroquinolone antibiotic [4], 
whilst the British Th   oracic Society recommends initiating 
a β-lactam/macrolide antibiotic combination [5].
Martin-Loeches and colleagues recently conducted a 
prospective, observational cohort, multicentre study 
involving 218 mechanically ventilated CAP patients to 
see what eﬀ  ect diﬀ  erent antibiotic combinations had on 
mortality [6]. Th  ese investigators reported that the 
addition of a macrolide, but not a ﬂ  uoroquinolone, to 
standard antibiotic therapy was associated with reduced 
mortality in patients admitted to critical care with CAP. 
Death in critical care occurred in 26.1% of individuals 
receiving combi  nation therapy with a macrolide, 
compared with 46.3% in those receiving ﬂ  uoroquinolones 
[6]. Th   ese results support data from other observational 
studies that suggest β-lactam/macrolide combinations 
oﬀ  er a survival advantage in severe CAP. Th  is body of 
data is not scientiﬁ   cally robust enough, however, to 
adequately answer the question of whether adding a 
macrolide to a β-lactam confers a survival advantage – 
this will only be satisfactorily addressed by a large 
prospective random  ised control trial.
In addition to activity against atypical bacteria, macro-
lides have ubiquitous immunomodulatory eﬀ  ects. Specu-
lat  ing how this group of drugs might oﬀ   er a survival 
advantage when added to a β-lactam is therefore of 
interest, and several plausible mechanisms exist. Treat-
ment of undiagnosed atypical pneumonia could occur 
since 53% of patients in the reported study had no 
microbiological diagnosis [6]; however, this seems 
unlikely as one might expect ﬂ   uoroquinolones to be 
equally eﬀ  ective [7]. More  over, studies limited to pneu-
mo  coccal disease demon  strate that addition of a macro-
lide improves survival [8]. It also seems improbable that 
synergistic killing is responsible, as equivalency with 
ﬂ  uoroquino  lones would be expected.
Many researchers have focused on the pleiotropic 
immunomodulatory eﬀ  ects [9] observed with macrolides 
as the reason why these agents may be beneﬁ  cial in CAP. 
Macrolides, at doses lower than those required for 
antibacterial activity, alter the production of cytokines 
and chemokines, and reduce cellular inﬁ  ltrates  and 
mucous production [9]. Th  e immunomodulatory eﬀ  ects 
of macrolides are illustrated by diﬀ  use panbronchiolitis. 
A chronic progressive lung disease found largely in Japan, 
diﬀ   use panbronchiolitis is characterised by mixed 
restrictive and obstructive pulmonary function, inter-
stitial inﬁ  ltrates and Pseudomonas aeruginosa infection. 
Long-term, low-dose macrolide treatment improves lung 
function and increases 10-year survival rates from 
around 15 to 90% [9].
Abstract
Combination therapy with two antimicrobial agents 
is superior to monotherapy in severe community-
acquired pneumonia, and recent data suggest that 
addition of a macrolide as the second antibiotic might 
be superior to other combinations. This observation 
requires confi  rmation in a randomised control trial, 
but this group of antibiotics have pleiotropic eff  ects 
that extend beyond bacterial killing. Macrolides inhibit 
bacterial cell-to-cell communication or quorum 
sensing, which not only might be an important 
mechanism of action for these drugs in severe 
infections but may also provide a novel target for the 
development of new anti-infective drugs.
© 2010 BioMed Central Ltd
Macrolides and community-acquired pneumonia: 
is quorum sensing the key?
Matt P Wise1*, David W Williams2, Michael AO Lewis2 and Paul J Frost1
COMMENTARY
*Correspondence: mattwise@doctors.org.uk
1Adult Critical Care, University Hospital of Wales, Cardiff   CF14 4XW, UK
Full list of author information is available at the end of the article
Wise et al. Critical Care 2010, 14:181 
http://ccforum.com/content/14/4/181
© 2010 BioMed Central LtdMacrolides are now being explored in new therapeutic 
strategies for a wide range of pulmonary and extra-
pulmonary conditions, including asthma, cystic ﬁ  brosis, 
rhinosinusitis, inﬂ  ammatory bowel disease, psoriasis and 
rosacea [9]. Clearly immunomodulatory eﬀ  ects could be 
important in altering mortality in CAP, but these drugs 
also have direct eﬀ  ects on bacteria through inhibiting 
quorum sensing.
Quorum sensing describes bacterial cell-to-cell 
communication that occurs as a function of changing cell 
density. Th   ese communication pathways are important in 
the pathogenesis of bacterial species causing human 
disease, including Staphylococcus aureus, Streptococcus 
pneumoniae, Escherichia coli and P. aeruginosa [10,11]. 
Quorum-sensing bacteria produce and release signal 
molecules or autoinducers, which regulate gene expres-
sion within the bacterial population and are closely 
linked to both bioﬁ   lm formation and expression of 
virulence factors. Bioﬁ  lms are structured populations of 
bacteria within a polysaccharide matrix, and these 
growth forms are more resistant to antibiotics. Th  e 
discovery of bioﬁ  lms as an entity did not occur until the 
late 1970s, and they are often still only considered in the 
context of chronic or device-associated infections; how-
ever, pneumonia caused by S. pneumoniae exists as a 
bioﬁ   lm in lung tissue [11]. Acute bacterial infections 
associated with bioﬁ  lm formation might also be relatively 
common. One of the diagnostic criteria for bioﬁ  lm 
infection is a culture-negative result despite a clinically 
documented infection [12], a situation encountered in 30 
to 50% of severe sepsis and septic shock [6].
Macrolides at subminimum inhibitory concentrations 
have been demonstrated to antagonise quorum sensing 
in P. aeruginosa, resulting in diminished virulence, bio-
ﬁ  lm formation and oxidative stress response [13]. Signiﬁ  -
cantly, inhibition of quorum sensing reduces pathogenicity 
of bacteria and impedes formation of antibiotic-resistant 
bioﬁ  lms, and therefore oﬀ  ers an attractive mechanism 
whereby the addition of a macrolide could reduce 
mortality in CAP [6]. If macrolides do confer additional 
eﬃ   cacy because of immunomodulatory eﬀ  ects or inhibi-
tion of quorum sensing, or both, one might expect them 
to be an eﬀ  ective therapeutic strategy applicable to many 
other infections encountered in critically ill patients. 
Indeed, the addition of clarithromycin to patients with 
ventilator-associated pneumonia accelerated resolution of 
pneumonia and weaning from mechanical ventilation [14].
It may be possible to approach the question of whether 
immunomodulation or inhibition of quorum sensing is 
more important in reducing mortality experimentally. 
Lesprit and colleagues described the important role of P. 
aeruginosa quorum sensing in rat pulmonary infection 
using the virulent wild-type strain P. aeruginosa PAO1 
and the less virulent mutant strain P. aeruginosa PAOR 
with a deﬁ  cient quorum-sensing pathway [15]. Using this 
model system it would be beneﬁ  cial to examine whether 
macrolides act predominantly through disrupting 
quorum sensing, as one would then expect to see little 
reduction in mortality caused by a large inoculum of the 
mutant PAOR but a signiﬁ  cant  eﬀ   ect on pneumonia 
caused by a smaller dose of the wild-type PAO1.
At a time when few new antimicrobial agents are being 
commercially developed for clinical use and the burden 
of infection caused by multiresistant bacteria is 
increasing, the need for novel approaches to the 
management of infection is essential. Quorum sensing 
determines both bacterial virulence and bioﬁ  lm 
formation; it is a common pathway for pathogens and 
represents an attractive new target for the development 
of drugs in the ﬁ  ght against infection [10].
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